Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update
May 10, 2022 08:00 ET
|
Eloxx Pharmaceuticals
Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating...
Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update
March 31, 2022 07:00 ET
|
Eloxx Pharmaceuticals
Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 Cystic Fibrosis Foundation (CF...
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome
March 30, 2022 16:15 ET
|
Eloxx Pharmaceuticals
Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical studies and is preferentially transported to kidney...
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation
March 29, 2022 07:00 ET
|
Eloxx Pharmaceuticals
Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program Expect topline data from cystic fibrosis Phase 2 expansion treatment...
Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
November 17, 2021 07:00 ET
|
Eloxx Pharmaceuticals
ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02...
Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update
November 09, 2021 08:00 ET
|
Eloxx Pharmaceuticals
Data from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Quarter of 2021 Received FDA Fast Track Designation for ELX-02 for the...
Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs
October 07, 2021 16:15 ET
|
Eloxx Pharmaceuticals
Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights Data from ongoing Phase 2 trials in CF expected in 4Q 2021 WATERTOWN, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eloxx...
Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital
October 05, 2021 08:00 ET
|
Eloxx Pharmaceuticals
WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules...
Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense Mutations
September 09, 2021 08:00 ET
|
Eloxx Pharmaceuticals
WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation...
Eloxx Pharmaceuticals Appoints Chief Medical Officer
September 08, 2021 08:00 ET
|
Eloxx Pharmaceuticals
WATERTOWN, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced the appointment of Ali Hariri, M.D., as its Chief Medical Officer, overseeing...